Cancer Prevention and Control Program (CPCP)

癌症的预防和控制 亚利桑那大学癌症中心（UACC）的癌症预防和控制计划（CPCP） 开展高度互动的跨学科癌症预防和控制研究，以减少癌症 负担CPCP坚持高度重视与流域相关的癌症研究， UACC集水区。具体目标是：（1）促进对癌症的了解和早期发现 通过识别风险因素和开发检测生物标志物和成像技术 （发现）;（2）评估新的癌症预防药物和策略，以减少癌症负担 （干预）;（3）实施循证行为、心理社会和系统层面的战略， 促进健康和改善成果（传播和实施）。CPCP成员已 癌症预防和控制研究在以下方面取得了重大进展：（1）证明 消防员暴露于致癌物质，改变他们的DNA甲基化模式，导致政策的变化; (2)确定了西班牙裔与非西班牙裔白人肾癌驱动因素的差异;（3）开发了一种 新的高灵敏度乳腺CT成像系统和智能手机共聚焦显微镜;（4）显示， 西兰花种子提取物上调烟草致癌物的解毒;（5）完成HPV疫苗给药 研究，通报了世界卫生组织的全球疫苗接种指南政策;（6）制定了一个高效的 支持拉丁裔乳腺癌幸存者和照顾者的症状管理计划;和（7） 将美国印第安人的癌症筛查率从9%提高到19%。CPCP有一个同行评审，癌症 890万美元（直接成本）的重点资金基础，其中600万美元（67%）来自国家癌症研究所（NCI）， 210万美元（24%）来自其他国家卫生研究院，80万美元（9%）来自其他同行评审 源值得注意的是，CPCP的NCI资金比上一个报告期报告的资金高出50%。 在报告期内，CPCP成员在33项同行评审的癌症相关多PI中获得了4700万美元的奖励。 赠款。这些MPI包括12个R 01，两个P01，一个U 54，以及与66个机构的伙伴关系。 国家，其中三个是国家癌症研究所指定的癌症中心。资金包括皮肤癌的新P01 预防;一项新的UG 1赠款，用于领导癌症预防药物的早期临床试验，这是仅有的五项 NCI资助的项目;新的疾病控制和预防中心癌症资金作为亚利桑那州的网站， 国家癌症预防临床试验网络;以及P42资金，以解决矿山废物暴露问题， 癌症宣传在本项目期间，CPCP成员撰写了525份与癌症相关的 其中122份（23%）为方案内出版物，76份（14%）为方案间出版物，311份（59%）为 机构间。此外，CPCP成员提交了59项专利，其中12项（20%）已被授予。期间 项目期间，CPCP累计8，941名参与者参加临床研究，其中6，496名参与者 与前一时期相比，药物启动的试验增加了2倍。

CANCER PREVENTION & CONTROL PROGRAM: ABSTRACT The Cancer Prevention & Control Program (CPCP) at the University of Arizona Cancer Center (UACC) conducts highly interactive, transdisciplinary cancer prevention and control research to reduce the cancer burden. CPCP maintains a strong emphasis on catchment-relevant cancer research that informs and impacts the UACC Catchment Area. The Specific Aims are to: (1) advance understanding and early detection of cancer through identification of risk factors and development of detection biomarker and imaging technologies (Discovery); (2) evaluate novel cancer preventive agents and strategies to reduce the cancer burden (Intervention); and (3) implement evidence-based behavioral, psychosocial, and system-level strategies to promote health and improve outcomes (Dissemination and Implementation). CPCP Members have made significant progress on cancer prevention and control research in the following areas: (1) demonstrated exposure of firefighters to carcinogens that alter their DNA methylation patterns, leading to changes in policy; (2) identified differences in drivers of renal cancer in Hispanics versus non-Hispanic Whites; (3) developed a new highly sensitive breast-CT imaging system and smartphone confocal microscope; (4) showed that a broccoli seed extract upregulated detoxification of tobacco carcinogens; (5) completed HPV vaccine dosing studies that informed on WHO policy for worldwide vaccination guideline; (6) developed a highly effective symptom management program for support of Latina breast cancer survivors and caregivers; and (7) increased cancer screening rates in American Indians from 9% to 19%. CPCP has a peer-reviewed, cancer focused funding base of $8.9M (direct costs) of which $6M (67%) is from the National Cancer Institute (NCI), $2.1M (24%) from other National Institutes of Health sources, and $0.8M (9%) from other peer-reviewed sources. Of note, CPCP’s NCI funding is 50% higher than that reported during the prior reporting period. During the reporting period, CPCP Members were awarded $47M in 33 peer-reviewed cancer-relevant multi-PI grants. These MPIs included 12 R01s, two P01s, one U54, and partnerships with 66 institutions across the country, of which three were NCI-designated cancer centers. Funding includes a new P01 in skin cancer prevention; a new UG1 grant to lead early-phase clinical trials of cancer preventive agents, one of only five NCI-funded programs; new Centers for Disease Control and Prevention cancer funding as the Arizona site for the national Cancer Prevention Clinical Trials Network; and P42 funding to address mine waste exposures and cancer promotion. During the current project period, CPCP Members authored 525 cancer-relevant publications, of which 122 (23%) were intraprogrammatic, 76 (14%) were interprogrammatic, 311 (59%) were inter-institutional. In addition, CPCP members filed 59 patents, of which 12 (20%) were issued. During the project period, CPCP accrued 8,941 participants to clinical studies, 6,496 of which were accrued to investigator-initiated trials representing a 2-fold increase compared to the prior period.